Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapy

5 Oct 2022

Abstract excerpt

Background Somatostatin receptor-2 (SSTR2) is expressed on cell surface of neuroendocrine neoplasias; its presence is exploited for the delivery of peptide receptor radionuclide therapy (PRRT). Patients with no or low expression of SSTR2 are not candidates for PRRT. SSTR2 promotor undergoes epigenetic modification, known to regulate gene expression. We investigated whether the demethylation agent, guadecitabine,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Metastases and Treatment
Share to Neuroendocrine Tumor Research Advances
Share to Radiopharmaceutical Chemistry and Applications

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36208569
DOI: 10.1016/j.ejca.2022.09.009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapyPMID 36208569Read ↗

Upregulation of Somatostatin Receptor Type 2 in a Receptor-Deficient <i>In Vivo</i> Pancreatic Neuroendocrine Tumor Model Improves Tumor Response to Targeted <sup>177</sup> Lu-DOTATATESemantic proximity Read ↗

A pan-cancer analysis of the clinical and genetic portraits of somatostatin receptor expressing-tumor as a potential target of peptide receptor imaging and therapySemantic proximity Read ↗

Multiple Epigenetic Mechanisms Functionally Cooperate to Silence Expression of Somatostatin Receptor Type 2 in Pancreatic Neuroendocrine TumorsSemantic proximity Read ↗

DNA-PKcs inhibitors sensitize neuroendocrine tumor cells to peptide receptor radionuclide therapy in vitro and in vivoSemantic proximity Read ↗

Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in VivoSemantic proximity Read ↗

A genome-wide CRISPR/Cas9 screen identifies DNA-PK as a sensitiser to 177 Lutetium-DOTA-octreotate radionuclide therapySemantic proximity Read ↗

Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARPSemantic proximity Read ↗

Somatostatin Receptor Based Imaging and Radionuclide TherapySemantic proximity Read ↗

Theranostics for Neuroblastoma: Making Molecular Radiotherapy Work BetterSemantic proximity Read ↗

Epigenetic regulation of SST2 expression in small intestinal neuroendocrine tumorsSemantic proximity Read ↗

Understanding the Radiobiological Mechanisms Induced by 177Lu-DOTATATE in Comparison to External Beam Radiation TherapySemantic proximity Read ↗

Epigenetic and post‐transcriptional regulation of somatostatin receptor subtype 5 (SST 5 ) in pituitary and pancreatic neuroendocrine tumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.